Technical Reports on Generic Drugs Equities -- Allergan, Ironwood Pharma, Medicines Co., and Catalent

Wednesday, July 19, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, July 19, 2017 /PRNewswire/ --

If you want a Stock Review on AGN, IRWD, MDCO, or CTLT then come over to and sign up for your free customized report today. The Generic Drugs market can be segmented into biosimilars, simple generic, and super generic. Based on its therapeutics applications, the market can be classified
into cardiovascular products, anti-infective drugs, anti-arthritis drugs, central nervous system drugs, anti-cancer drugs, respiratory products, and others. This morning, monitors Allergan PLC (NYSE: AGN), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), The Medicines Co. (NASDAQ: MDCO), and Catalent Inc. (NYSE: CTLT). Learn more about these stocks by downloading their comprehensive and free reports from member's area at:


On Tuesday, shares in Dublin, Ireland headquartered Allergan PLC saw a slight decline of 0.73%, ending the day at $245.73. The stock recorded a trading volume of 1.43 million shares. The Company's shares have advanced 4.35% in the last one month, 4.84% over the previous three months, and 17.01% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 4.72% and 8.75%, respectively. Moreover, shares of Allergan, which develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide, have a Relative Strength Index (RSI) of 63.38.

On July 13th, 2017, Allergan announced its support of the White Dress Project and its efforts to expand uterine fibroid education and awareness. The Company's Women's Health franchise is providing a donation to help the organization push for Uterine Fibroid Awareness Month to be observed throughout the US Currently, only New York, Florida, and Georgia have passed resolutions, marking July as Uterine Fibroid Awareness Month. AGN complete research report is just a click away at:

Ironwood Pharma 

Shares in Cambridge, Massachusetts headquartered Ironwood Pharmaceuticals Inc. ended the day 1.11% lower at $18.78 with a total trading volume of 763,220 shares. In the last month and the previous three months, the stock has gained 6.77% and 21.32%, respectively. Additionally, the Company's shares have advanced 22.83% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 2.76% and 14.57%, respectively. Furthermore, shares of Ironwood Pharma, which engages in the research, development, and commercialization of human therapeutic products, have an RSI of 49.77. The complimentary report on IRWD can be downloaded at:

Medicines Co. 

At the close of trading on Tuesday, shares in Parsippany, New Jersey-based The Medicines Co. finished 1.41% lower at $37.76. A total volume of 1.33 million shares was traded, which was above their three months average volume of 1.23 million shares. The stock has advanced 1.81% in the last one month and 11.26% on an YTD basis. The Company's shares are trading below their 50-day moving average by 6.36%. Additionally, shares of Medicines Co., which provides medicines for patients in acute and intensive care hospitals worldwide, have an RSI of 40.64. Sign up for your complimentary research report on MDCO at:


Somerset, New Jersey headquartered Catalent Inc.'s shares recorded a trading volume of 666,461 shares at the end of yesterday's session. The stock closed the day 0.36% lower at $35.76. The Company's shares have advanced 28.68% in the previous three months and 32.64% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 0.86% and 23.84%, respectively. Additionally, shares of Catalent, which provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products worldwide, have an RSI of 50.74. Get free access to your research report on CTLT at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store